Big Cypress Acquisition priced its $100 million IPO at $10 per unit. The upsize was a a 33 percent increase from the initial filing in December to offer 75 million units.
The new SPAC plans to target a business in the life sciences industry.
Big Cypress is led by CEO Samuel J. Reich, who co-founded Biscayne Neurotherapeutics in 2011 and served as its executive chairman until the company was sold Supernus Pharmaceuticals in 2018.
The SPAC trades on the Nasdaq under BCYPU.
